Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study
• This report provides in-depth analysis of the global cutaneous squamous-cell carcinoma treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cutaneous squamous-cell carcinoma treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global cutaneous squamous-cell carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.
Cutaneous Squamous Cell Carcinoma Treatment Market Segmentation
• By Treatment Insights
o Surgical
 Moh’s Micrographic Surgery (MMS)
 Electrodessication or Curettage
o Non-surgical
 Chemotherapy
 Topical Immune Response Modifiers
 Radiotherapy
 Systemic Chemotherapy
• By Application Insights
o Hospitals
o Cancer Institutes
o Ambulatory Surgical Centers
o Others
• By Region Insights
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Argentina
 Mexico
 Rest of Latin America
o Europe
 Germany
 U.K.
 Spain
 France
 Italy
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East & Africa
 GCC Countries
 Israel
 Rest of Middle East & Africa
• Key Players in the Cutaneous Squamous Cell Carcinoma Treatment Market
o Eli Lilly and Company
o Sanofi S.A.
o Cadila Healthcare Limited
o Cipla Limited
o Castle Biosciences
o Regeneron Pharmaceuticals, Inc
o Merck & Co., Inc
o Vidac Pharma
o LEO Pharma A/S
o Merck Sharp & Dohme
o Amgen Inc

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 Market Snippet, By Treatment
 Market Snippet, By Application
 Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
 Drivers
 Restraints
 Market Opportunities
o Impact Analysis
o Pipeline Analysis
o Reimbursement Scenario
o Epidemiology
o Pest Analysis
o Regulatory Scenario
o New Product Launches
o Collaborations and Agreements
o Market Trends
4. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 – 2033
 Segment Trends
o Surgical
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Moh’s Micrographic Surgery (MMS)
o Electrodessication or Curettage
o Non-surgical
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Chemotherapy
o Topical Immune Response Modifiers
o Radiotherapy
o Systemic Chemotherapy
5. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 – 2033
 Segment Trends
o Hospitals
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Cancer Institutes
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Ambulatory Surgical Centers
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
 Market Share Analysis, By Region, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, For Regions, 2022–2033
o North America
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
 Market Size and Forecast, By Treatment, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Application, 2021 – 2033, (USD Mn)
 Market Size and Forecast, By Country/Region, 2021 – 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
 Eli Lilly and Company
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Sanofi S.A.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Cadila Healthcare Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Cipla Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Castle Biosciences
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Regeneron Pharmaceuticals, Inc
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Merck & Co., Inc
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Vidac Pharma
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 LEO Pharma A/S
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Regeneron Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Merck Sharp & Dohme
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
 Amgen Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About us and Sales Contact